Karsten Spiekermann

16.3k total citations
178 papers, 5.5k citations indexed

About

Karsten Spiekermann is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Karsten Spiekermann has authored 178 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 129 papers in Hematology, 76 papers in Molecular Biology and 43 papers in Genetics. Recurrent topics in Karsten Spiekermann's work include Acute Myeloid Leukemia Research (116 papers), Chronic Myeloid Leukemia Treatments (41 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (24 papers). Karsten Spiekermann is often cited by papers focused on Acute Myeloid Leukemia Research (116 papers), Chronic Myeloid Leukemia Treatments (41 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (24 papers). Karsten Spiekermann collaborates with scholars based in Germany, United States and New Zealand. Karsten Spiekermann's co-authors include Wolfgang Hiddemann, Stefan K. Bohlander, Klaus H. Metzeler, Susanne Schnittger, Wolfgang Hiddemann, Jan Braess, Tobias Kohl, Marion Subklewe, Ksenia Bagrintseva and Christian Buske and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Karsten Spiekermann

163 papers receiving 5.5k citations

Peers

Countries citing papers authored by Karsten Spiekermann

Since Specialization

Citations

This map shows the geographic impact of Karsten Spiekermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karsten Spiekermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karsten Spiekermann more than expected).

Fields of papers citing papers by Karsten Spiekermann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karsten Spiekermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karsten Spiekermann. The network helps show where Karsten Spiekermann may publish in the future.

Co-authorship network of co-authors of Karsten Spiekermann

This figure shows the co-authorship network connecting the top 25 collaborators of Karsten Spiekermann. A scholar is included among the top collaborators of Karsten Spiekermann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karsten Spiekermann. Karsten Spiekermann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical features, course, and risk factors of infection-associated secondary hemophagocytic lymphohistiocytosis 2025 ·Infection ·(unknown), (unknown), Hans‐Joachim Stemmler, Stephanie-Susanne Stecher, Hendrik Schulze‐Koops, Fabian Hauck, (unknown), (unknown), Karsten Spiekermann	0
2	Mechanosensing via a GpIIb/Src/14-3-3ζ axis critically regulates platelet migration in vascular inflammation 2023 ·Blood ·Rainer Kaiser, Afra Anjum, (unknown), (unknown), (unknown), (unknown), Raphael Escaig, (unknown), (unknown), Michael Lorenz, Christoph Gold, Kami Pekayvaz, Thomas Brocker, Jan Kranich, Julian Walter Holch, Karsten Spiekermann, Steffen Maßberg, Florian Gaertner, Leo Nicolai	9
3	Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia 2023 ·Leukemia ·Christian Rausch, Maja Rothenberg‐Thurley, Annika Dufour, Stephanie Schneider, (unknown), Cristina Sauerland, Dennis Görlich, Utz Krug, Wolfgang E. Berdel, Bernhard J. Woermann, Wolfgang Hiddemann, Jan Braess, Michael von Bergwelt‐Baildon, Karsten Spiekermann, Tobias Herold, Klaus H. Metzeler	45
4	WT1 and DNMT3A play essential roles in the growth of certain patient AML cells in mice 2022 ·Blood ·(unknown), (unknown), (unknown), (unknown), Binje Vick, Karsten Spiekermann, Maja Rothenberg‐Thurley, Klaus H. Metzeler, Anetta Marcinek, Marion Subklewe, Michael P. Menden, Vindi Jurinović, Ehsan Bahrami, Irmela Jeremias	1
5	A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy 2022 ·Annals of Hematology ·(unknown), Raphael Koch, Joachim Gerß, Marcus Hentrich, Rudolf Peceny, Tobias Bartscht, Björn Steffen, (unknown), Karsten Spiekermann, Linus Angenendt, Jan‐Henrik Mikesch, (unknown), Trude Butterfaß‐Bahloul, Hubert Serve, Georg Lenz, Wolfgang E. Berdel, Utz Krug, Christoph Schliemann	1
6	sCD25 as an independent adverse prognostic factor in adult patients with HLH: results of a multicenter retrospective study 2022 ·Blood Advances ·(unknown), (unknown), Hans‐Joachim Stemmler, Fabian Hauck, Hendrik Schulze‐Koops, Stephanie-Susanne Stecher, Michael Starck, Clemens‐Martin Wendtner, Peter Bojko, Marcus Hentrich, (unknown), Katharina S. Götze, Florian Bassermann, Michael von Bergwelt‐Baildon, Karsten Spiekermann	11
7	Treatment, outcome and re-vaccination of patients with SARS-CoV-2 vaccine-associated immune thrombocytopenia 2022 ·Infection ·(unknown), (unknown), Lars H. Lindner, Martin Dreyling, Michael von Bergwelt‐Baildon, Stefan Boeck, Clemens Gießen-Jung, Valeria Milani, Hans‐Joachim Stemmler, Marion Subklewe, Oliver Weigert, Karsten Spiekermann	1
8	Therapy‐Induced Senescence Is a Predictor of Treatment Outcome in Acute Myeloid Leukemia 2017 ·Blood ·Martin Schönlein, J. Henry M. Däbritz, Dorothy Ngo-Yin Fan, Jana Ihlow, Rolf Schwarzer, Binje Vick, Karsten Spiekermann, Thomas Burmeister, Jörg Westermann, Irmela Jeremias, Clemens A. Schmitt	2
9	Persistence of Driver Mutations during Complete Remission Associates with Shorter Survival and Contributes to the Inferior Outcomes of Elderly Patients with Acute Myeloid Leukemia 2016 ·Haematologica ·Maja Rothenberg‐Thurley, Susanne Amler, Dennis Göerlich, M. C. Sauerland, S. Schneider, Nikola P. Konstandin, Sebastian Schaaf, Aarif M.N. Batcha, Kathrin Bräundl, Bianka Ksienzyk, Evelyn Zellmeier, Ulrich Mansmann, Michael Fiegl, Marion Subklewe, Stefan K. Bohlander, Andreas Faldum, Wolfgang Hiddemann, Karsten Spiekermann, Jan Braess, Klaus H. Metzeler	2
10	Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia 2014 ·Leukemia ·(unknown), Klaus H. Metzeler, (unknown), Tobias Herold, (unknown), (unknown), Michela Carlet, Gina Walter, Tanja Hinrichsen, (unknown), M Grunert, Simon Schneider, Marion Subklewe, A Dufour, Stefan Fröhling, Klein Hg, Wolfgang Hiddemann, Irmela Jeremias, Karsten Spiekermann	58
11	Breakdown of the FLT3-ITD/STAT5 Axis and Synergistic Apoptosis Induction by the Histone Deacetylase Inhibitor Panobinostat and FLT3-Specific Inhibitors 2012 ·Molecular Cancer Therapeutics ·(unknown), Hella Anna Bolck, Marc Buchwald, (unknown), Harald Polzer, Karsten Spiekermann, Gesine Bug, Thorsten Heinzel, (unknown), Oliver H. Krämer	42
12	Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients 2012 ·Annals of Hematology ·(unknown), Annika Dufour, Friederike Schneider, Eva Hoster, Tobias Benthaus, Bianka Ksienzyk, Stephanie Schneider, Purvi M. Kakadia, Maria‐Cristina Sauerland, Wolfgang E. Berdel, Thomas Büchner, Bernhard Wörmann, Jan Braess, Marion Subklewe, Wolfgang Hiddemann, Stefan K. Bohlander, Karsten Spiekermann	27
13	High expression ofMZB1predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signature 2012 ·Leukemia & lymphoma ·Tobias Herold, Medhanie Mulaw, Vindi Jurinović, Till Seiler, Klaus H. Metzeler, Annika Dufour, Stephanie Schneider, Purvi M. Kakadia, Karsten Spiekermann, Ulrich Mansmann, Wolfgang Hiddemann, Christian Buske, Martin Dreyling, Stefan K. Bohlander	23
14	Chronic Granulomatous Disease in an Adult Recognized by an Invasive Aspergillosis 2011 ·The American Journal of the Medical Sciences ·Inès Kaufmann, Josef Briegel, Verena van der Heide, Alexander Choukèr, Lorenz Frey, Karsten Spiekermann, Doris Mayr, Manfred Thiel	3
15	CBL Exon 8/9 Mutants Activate the FLT3 Pathway and Cluster in Core Binding Factor/11q Deletion Acute Myeloid Leukemia/Myelodysplastic Syndrome Subtypes 2009 ·Clinical Cancer Research ·Carola Reindl, Hilmar Quentmeier, Konstantin Petropoulos, Philipp A. Greif, Tobias Benthaus, Bob Argiropoulos, Gudrun Mellert, Sridhar Vempati, Justus Duyster, Christian Buske, Stefan K. Bohlander, R. Keith Humphries, Wolfgang Hiddemann, Karsten Spiekermann	89
16	Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical Outcome 2009 ·Journal of Clinical Oncology ·Annika Dufour, Friederike Schneider, Klaus H. Metzeler, Eva Hoster, Stephanie Schneider, Evelyn Zellmeier, Tobias Benthaus, Maria‐Cristina Sauerland, Wolfgang E. Berdel, Thomas Büchner, Bernhard Wörmann, Jan Braess, Wolfgang Hiddemann, Stefan K. Bohlander, Karsten Spiekermann	189
17	NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS) 2009 ·Blood ·Friederike Schneider, Eva Hoster, Michael Unterhalt, Stephanie Schneider, Annika Dufour, Tobias Benthaus, Gudrun Mellert, (unknown), Stefan K. Bohlander, Michaela Feuring‐Buske, Christian Buske, Jan Braess, Susanne Fritsch, Achim Heinecke, Maria Cristina Sauerland, Wolfgang E. Berdel, Thomas Buechner, Bernhard J. Woermann, Wolfgang Hiddemann, Karsten Spiekermann	48
18	Transformation by Oncogenic Mutants and Ligand-Dependent Activation of FLT3 Wild-type Requires the Tyrosine Residues 589 and 591 2008 ·Clinical Cancer Research ·Sridhar Vempati, Carola Reindl, (unknown), (unknown), Konstantin Petropoulos, Vegi M. Naidu, Christian Buske, Wolfgang Hiddemann, Tobias Kohl, Karsten Spiekermann	23
19	Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group 2008 ·Journal of Clinical Oncology ·Thomas Büchner, Wolfgang E. Berdel, Claudia Haferlach, Torsten Haferlach, Susanne Schnittger, Carsten Müller‐Tidow, Jan Braess, Karsten Spiekermann, Joachim Kienast, Peter Staib, Andreas Grüneisen, Wolfgang Kern, Albrecht Reichle, Georg Maschmeyer, Carlo Aul, Eva Lengfelder, Maria‐Cristina Sauerland, Achim Heinecke, Bernhard Wörmann, Wolfgang Hiddemann	232
20	The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells 2002 ·Experimental Hematology ·Karsten Spiekermann, Florian Faber, Robert Voswinckel, Wolfgang Hiddemann	51

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact